Instrumentation Laboratory Launches HemosIL® ReadiPlasTin® Assay Worldwide
-- Liquid, Ready-to-Use PT Reagent for Enhanced Efficiency and Accuracy --
Aug 15, 2016, 08:30 ET
BEDFORD, Mass., Aug. 15, 2016 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced the commercialization of HemosIL ReadiPlasTin, a new PT reagent, in markets throughout the world, expanding the Company's growing portfolio of liquid, ready-to-use assays. The analytical performance of HemosIL ReadiPlasTin is equivalent to the Company's gold-standard HemosIL RecombiPlasTin® 2G assay. Both reagents offer high sensitivity, low ISI ≈1.0, with recombinant human tissue factor and synthetic phospholipids, providing lot-to-lot consistency. Additionally, HemosIL ReadiPlasTin does not require pipetting and acclimation time, reducing manual reagent handling and reconstitution errors.
"By eliminated pipetting and wait time, HemosIL ReadiPlasTin virtually eliminates human error and drastically reduces preparation time for one of the most common tests performed in labs today," said Remo Tazzi, Director Worldwide Hemostasis Marketing at IL. "This important addition to our broad portfolio of liquid-ready-to-use reagents reinforces our commitment to helping laboratories achieve greater efficiency while improving patient care."
HemosIL ReadiPlasTin is fully validated for use and stable for up to ten days in original vials on ACL TOP Family and new ACL TOP Family 50 Series* Hemostasis Testing Systems. It is available in 10 and 20 mL formats.
The leading manufacturer of instruments and reagents for the Hemostasis market worldwide, IL been at the forefront of innovation in hemostasis testing for more than thirty years. Recently, the Company introduced the ACL TOP Family 50 Series Hemostasis Testing Systems with automated pre-analytical sample checks. The ACL TOP Family of fully automated analyzers is the leading Hemostasis product line in the world.
About Prothrombin Time
Prothrombin Time (PT) is a global test of the extrinsic and common pathways of coagulation. It is commonly used to screen for inherited and acquired coagulation disorders and to monitor warfarin therapy.1
*Not available in all countries.
Reference
- Kottke-Marchant K. Algorithmic Approaches to Hemostasis Testing. Semin Thromb Hemost. 2014;40(02):195-204.
Instrumentation Laboratory (www.instrumentationlaboratory.com), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The Company's product lines include Critical Care systems, Hemostasis systems and Information Management systems. IL GEM® product offerings, part of the Critical Care line, include the GEM Premier™ 4000 analyzer with Intelligent Quality Management (iQM®), GEM Premier 3500 and GEMweb® Plus Custom Connectivity. The IL Hemostasis portfolio includes new ACL TOP Family 50 Series Hemostasis Testing Systems and the original ACL TOP® Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers. IL also offers the ACL AcuStar®, ACL Elite®, and other Hemostasis analyzers, along with the comprehensive HemosIL® line of reagents. IL is based in Bedford, Massachusetts.
The Instrumentation Laboratory logo, GEM, GEMweb, iQM, HemosIL, ACL, ACL TOP, ACL Elite, ACL AcuStar, ReadiPlasTin, RecombiPlastin and Premier are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies, and may be registered in the United States Patent and Trademark Office and in other jurisdictions. All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.
Logo - http://photos.prnewswire.com/prnh/20140204/NE58020LOGO
SOURCE Instrumentation Laboratory